1/6 Our JCO piece @guptaarjun90 on the need to improve communication training in #medonc fellowship. Every day oncologists deliver bad news. The words we choose impact pts & caregivers. Our training does not reflect the gravity of this @tmprowell @AAHPM https://t.co/EAxrQcS9rb

Thirty Years of Ortho: What I’d Tell the Next Generation I’ve been an orthopedic surgeon for three decades. Long enough to see techniques come and go, implants rise and fall, and the pendulum of “standard practice” swing back and forth more times than I can count. What hasn’t

😮 Wow, how horrible. Significantly reduced lifespan. Not even just breast cancer, have to focus on how we can reduce all cause mortality for pts who harbor BRCA alterations! Oophorectomy, for example, increases comorbidity and death risk with early menopause. #SABCS25

OlympiaN study by Nadine Tung Preop Olaparib alone or with durvalumab in pts w/ BRCAm and ER-neg or low, HER2-neg Cohort A: olaparib (T1bc/N0) pCR 68% (RCB 0/1 72%) Cohort B: olaparib + durva (cT2N0) pCR 80% (RCB 0/1 84%) @DFCI_BreastOnc @OncoAlert #SABCS25

@SpineNeuro I’m a 40-year-old surgeon 10 years into my career being asked to take a course on how to hand wash. Wish I was lying.

RxPONDER Cognitive substudy now out in @JAMAOnc Chemo-ET: greater negative impact on pt-reported cognitive fnx vs ET alone in pre/post menopausal persistent over 36 mo Further supports value of selecting pts who can avoid chemo @KalinskyKevin @lynnhenrymd @irenekangmd

🧠💊 Do CDK4/6 inhibitors worsen cognition in HR+ HER2− advanced breast cancer? SONIA-EfFECT answers this clearly 👇 🔬 Study 260 pts with HR+ HER2− ABC AI + CDK4/6i vs AI alone Cognition tested at baseline and 9 months 📊 Key numbers • Baseline cognitive impairment: 46.5%

NSABP B-59/Gepardouze ctDNA substudy (Exact sciences assay) n=212 BL 96% MRD+ Post NAT: 9% Post surgery: 6% 30-fold increase risk of distant recurrence if MRD + post surgery 95% of pts MRD negative post surgery remain free of disease at 3 yrs @oncolaert #SABCS25

PATINA demonstrates lower rates of CNS progression in both all pts and those with brain meta at baseline with the addition of palbociclib. @Otto_DFCI @OncoAlert #SABCS25

ctDNA positive status highly prognostic at all time points in the phase 3 PALLAS trial. Excellent presentation by ⁦@hthrparsons⁩ on behalf of global PALLAS team ⁦@ABCSGVienna⁩ ⁦@ALLIANCE_org⁩ #SABCS25 ⁦@MichaelGnant⁩ ⁦@AngieDemichele⁩

Fascinating commentary (on an earlier @Nature paper) describing how aspirin prevents mets. Much still to be learned about the interactions of platelets and cancer biology https://t.co/Q2zgiceWdI

Deeply grateful to my mentor, Dr. Sedrak @minasedrakmd, for the continued guidance, encouragement, and belief in me. Your support inspires me every day, and I’m grateful for the opportunity to learn and grow under your mentorship. Mentorship truly shapes careers - thank you with

In this secondary analysis of the RxPONDER trial, chemoendocrine therapy was associated with greater and more persistent self-reported cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women with #BreastCancer. https://t.co/HOXeZTRtcH

Do patients with LMD benefit from Dato-DXd? The #DATOBASE phase 2 trial found 30% icORR, with OS 4.7 mo — but OS up to 13.3 mo in ADC-naive patients. Improvement in neurological symptoms in most patients. Two cohorts keep enrolling. Lucky to be working on this with @drsarahsam!

Management of Cancer During Pregnancy: ASCO Guideline It is a remarkably comprehensive guide that addresses every question thoroughly👇 https://t.co/NXtQjTcsIb

This is profound: we are consuming more of patients’ and caregivers’ lives just to receive care. I wonder if this reflects the commensurate increase in administrators who prioritize efficiency & margin? We need innovation in care delivery to intervene on this real issue

Amazing work by @guptaarjun90 - showing the worsening “time toxicity” over 20 years for older adults w/ metastatic cancer in the year after diagnosis. Sadly, without a commensurate survival gain

AMBRE trial: Does 1L chemo (+/- ET/abema maintenance) improve outcomes for patients with high-burden HR+/HER2- MBC? No — better PFS, ORR and DoR with upfront ET+abemaciclib. With multiple trials reporting on this question, we now have a quite definitive response. #SABCS25

WOW! 🤩 Just fantastic to see this slide showing visually what we all know. Pace of improvement in breast cancer is fast 🏎️! 👏 to all researchers, participants on trials, and our @FDAOncology colleagues who do an unbelievable amount of work for these approvals! #SABCS25

#SABCS25 delivered one of the strongest collections of practice-changing data we’ve seen in years — reshaping treatment across TNBC, HR+/HER2–, HER2-low/ultralow, and metastatic disease. Here are the Top 10 abstracts that will meaningfully influence real-world oncology:

Patient advocate @amybeumer gives another master class on the patient experience #SABCS25 @SABCSSanAntonio @OncoAlert